[New aspects of therapy for alveolitis with Grisaldon].
In the GDR, Grisaldon has been used in alveolitis therapy since 1974. The results from the bacteriological testing of this preparation and the diluting and rinsing effects of saliva and blood on it arouse doubts about its antibacterial efficiency. Thrombelastographic studies demonstrated the clotting-accelerating and the marked fibrin-stabilizing effect of pure acetylsalicylic acid. In contrast to other publications, it was stated that the p-hydroxybenzoic acid propyl ester is absolutely indifferent. Histological studies on animals have shown that Grisaldon is detectable in the alveolus as a foreign body even 28 days after application, and that it decelerates wound healing.
D001241:Aspirin / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004341:Drug Evaluation; D004368:Dry Socket / Q000188:drug therapy*; D005549:Foreign-Body Reaction; D006801:Humans; D014945:Wound Healing / Q000187:drug effects
D001565:Benzoates; D004338:Drug Combinations; D001241:Aspirin
Neue Aspekte zur Therapie der Alveolitis mit Grisaldon.